Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.

View Abstract

AIM

To assess the risk of pneumonia among COPD patients using salmeterol/fluticasone propionate combination inhalers (SFC), inhaled corticosteroids (ICS), or long-acting beta-agonists (LABA), alone or in combination, compared to those using only short-acting bronchodilators (SABD).

METHOD

The study population comprised 5245 individuals using inhaled treatment for COPD, identified from the databases of three large regional managed care organisations from different parts of the USA. Longitudinally-collected administrative data were obtained on their clinical histories and treatments. Nested case-control methods were used to calculate adjusted odds ratios (OR) for the risk of pneumonia while on therapy.

RESULTS

2154 patients had at least one diagnosed case of pneumonia between 1st September 2001 and 31st August 2003. Relative to SABD, the only treatment associated with a non-significant increased risk of pneumonia was ICS used alone (OR=1.29; 95%CI: 0.96-1.73; p=0.09). Users of LABA alone (OR=0.92; 95%CI: 0.69-1.22) or SFC (OR=1.03; 95%CI: 0.74-1.42) had no increased risk for pneumonia relative to SABD. Advanced age and severity of lung disease were strongly associated with increased risk for pneumonia.

CONCLUSION

Treatment with ICS or an ICS/LABA combination inhaler was not associated with a significantly increased risk of developing pneumonia.

Investigators
Abbreviation
Prim Care Respir J
Publication Date
2010-01-15
Volume
19
Issue
2
Page Numbers
109-17
Pubmed ID
20082059
Medium
Print
Full Title
Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.
Authors
Mapel D, Schum M, Yood M, Brown J, Miller D, Davis K